|
CLINICAL TRIAL Trial No ClinicalTrials.gov ID |
Principal Investigator
Coordinator |
||
|---|---|---|---|
|
A Phase 2 Study of Blinatumomab in Combination With Nivolumab, a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ? 1 to < 31 Years Old With First Relapse
COG-AALL1821 NCT04546399  Recruiting
|
CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE
|
Acute Lymphocytic Leukemia |
Dr. Yvan Samson |
Groupe d'étude en oncologie du Québec